<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091507</url>
  </required_header>
  <id_info>
    <org_study_id>165</org_study_id>
    <secondary_id>U01HL077826</secondary_id>
    <secondary_id>U01HL077823</secondary_id>
    <secondary_id>U01HL077822</secondary_id>
    <secondary_id>U01HL077821</secondary_id>
    <nct_id>NCT00091507</nct_id>
  </id_info>
  <brief_title>IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.</brief_title>
  <acronym>IMMEDIATE</acronym>
  <official_title>Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the impact of pharmacological myocardial metabolic
      support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the
      treatment of patients with threatened or established acute myocardial infarction (AMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Basic and clinical research suggests intravenous GIK metabolic myocardial support reduces
      ischemia-induced arrhythmias, progression from unstable angina pectoris (UAP) to acute
      myocardial infarction (AMI), myocardial infarction (MI) size, and mortality. Also, for ST
      elevation MI (STEMI), GIK may prolong time of benefit of coronary reperfusion. These effects
      should reduce short- and long-term mortality from ACS, including AMI and UAP, and the
      propensity for heart failure (HF). These benefits are related to the earliness of ACS, when
      both risk and opportunity to save lives are highest.

      DESIGN NARRATIVE:

      This is a randomized, placebo-controlled, double-blinded, multicenter clinical trial of
      IMMEDIATE GIK as early as possible in ACS in the prehospital emergency medical service (EMS)
      setting. Distinct from prior and ongoing GIK trials, this will test GIK for all ACS rather
      than only for AMI or STEMI in prehospital EMS. The primary hypothesis is that early GIK will
      prevent or reduce the size of acute myocardial infarction. Major secondary hypotheses posit
      GIK will reduce mortality (30 days and 1 year), reduce pre- or in-hospital cardiac arrest and
      the propensity for heart failure. Other hypotheses address mechanisms of these effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of Acute Coronary Syndrome to Myocardial Infarction</measure>
    <time_frame>24 hours</time_frame>
    <description>Outcome for all participants during the first 24 hours of hospitalization; evidence of myocardial infarction is determined by ECG and biomarker results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Arrest</measure>
    <time_frame>1 to 18 hours (From prehospital setting through hospitalization.)</time_frame>
    <description>Outcome for all participants who had a cardiac arrest from initial contact in the prehospital setting through their subsequent hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure or Death</measure>
    <time_frame>30 days</time_frame>
    <description>Outcome for all participants (composite of re-hospitalization for heart failure or death within 30 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Outcome for all participants (mortality at 30 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Arrest or Acute Mortality</measure>
    <time_frame>Prehospital setting through hospitalization</time_frame>
    <description>Outcome for all participants (composite of cardiac arrest or acute mortality)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">911</enrollment>
  <condition>Angina, Unstable</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>1 -- GIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 -- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIK</intervention_name>
    <description>Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.</description>
    <arm_group_label>1 -- GIK</arm_group_label>
    <other_name>Glucose-Insulin Potassium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.</description>
    <arm_group_label>2 -- Placebo</arm_group_label>
    <other_name>Dextrose 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of threatened or established AMI including but not limited to:

               1. Chest pain, discomfort, or tightness

               2. Arm or shoulder pain

               3. Jaw pain

               4. Epigastric discomfort

               5. Shortness of breath

          -  12-lead electrocardiogram (ECG) with two or more contiguous leads with ST elevation
             greater than 1 mm, ST depression greater than 0.5 mm, T wave inversion or other T wave
             abnormalities (hyperacute T waves), or left bundle branch block (not known to be old).
             Identification aided by the acute cardiac ischemia time-insensitive predictive
             instrument (ACI-TIPI)and thrombolytic predictive instrument (TPI) decision support
             software (ACI-TIPI &gt;= 75% and TPI detection of suspected STEMI).

        Exclusion Criteria:

          -  End-stage kidney failure requiring dialysis

          -  Rales present more than halfway up the back

          -  Unable to comply with the requirements of the study

          -  Incarcerated

          -  Known to be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Selker, MD, MSPH</last_name>
    <role>Study Chair</role>
    <affiliation>Tufts Medical Center, Trial Coordinating Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph D'Agostino, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center, Data Coordinating Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Udelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center, LV Core Lab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anchorage Site</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Haven Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macon Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brockton Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Site</name>
      <address>
        <city>Concord</city>
        <state>Massachusetts</state>
        <zip>01742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hershey Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sioux Falls Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellingham Site</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milwaukee Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Selker HP, Beshansky JR, Ruthazer R, Sheehan PR, Sayah AJ, Atkins JM, Aufderheide TP, Pirrallo RG, D'Agostino RB, Massaro JM, Griffith JL. Emergency medical service predictive instrument-aided diagnosis and treatment of acute coronary syndromes and ST-segment elevation myocardial infarction in the IMMEDIATE trial. Prehosp Emerg Care. 2011 Apr-Jun;15(2):139-48. doi: 10.3109/10903127.2010.545478.</citation>
    <PMID>21366431</PMID>
  </reference>
  <reference>
    <citation>Selker HP, Beshansky JR, Griffith JL, D'Agostino RB, Massaro JM, Udelson JE, Rashba EJ, Ruthazer R, Sheehan PR, Desvigne-Nickens P, Rosenberg YD, Atkins JM, Sayah AJ, Aufderheide TP, Rackley CE, Opie LH, Lambrew CT, Cobb LA, Macleod BA, Ingwall JS, Zalenski RJ, Apstein CS. Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical services. Am Heart J. 2012 Mar;163(3):315-22. doi: 10.1016/j.ahj.2012.02.002.</citation>
    <PMID>22424000</PMID>
  </reference>
  <reference>
    <citation>Ellis KL, Zhou Y, Rodriguez-Murillo L, Beshansky JR, Ainehsazan E, Selker HP, Huggins GS, Cupples LA, Peter I. Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial. Pharmacogenomics J. 2017 Jan;17(1):76-83. doi: 10.1038/tpj.2015.84. Epub 2015 Dec 8.</citation>
    <PMID>26644202</PMID>
  </reference>
  <reference>
    <citation>Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Selker HP, Cupples LA, Huggins GS, Peter I. Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE trial. Pharmacogenomics J. 2015 Dec;15(6):488-95. doi: 10.1038/tpj.2015.10. Epub 2015 Mar 17.</citation>
    <PMID>25778467</PMID>
  </reference>
  <reference>
    <citation>Alkofide H, Huggins GS, Beshansky JR, Ruthazer R, Peter I, Ray M, Mukherjee JT, Selker HP. C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes. BMC Cardiovasc Disord. 2015 Dec 3;15:163. doi: 10.1186/s12872-015-0153-7.</citation>
    <PMID>26631004</PMID>
  </reference>
  <reference>
    <citation>Alkofide H, Huggins GS, Ruthazer R, Beshansky JR, Selker HP. Serum adiponectin levels in patients with acute coronary syndromes: Serial changes and relation to infarct size. Diab Vasc Dis Res. 2015 Nov;12(6):411-9. doi: 10.1177/1479164115592638. Epub 2015 Jul 20.</citation>
    <PMID>26193887</PMID>
  </reference>
  <results_reference>
    <citation>Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012 May 9;307(18):1925-33. doi: 10.1001/jama.2012.426. Epub 2012 Mar 27.</citation>
    <PMID>22452807</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2004</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <results_first_submitted>November 13, 2012</results_first_submitted>
  <results_first_submitted_qc>December 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2013</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GIK --</title>
          <description>GIK = glucose-insulin-potassium</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Dextrose 5%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="460"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GIK --</title>
          <description>GIK = glucose-insulin-potassium</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Dextrose 5%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="432"/>
            <count group_id="B2" value="479"/>
            <count group_id="B3" value="911"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="13.9"/>
                    <measurement group_id="B2" value="63.3" spread="14.1"/>
                    <measurement group_id="B3" value="63.6" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="479"/>
                    <measurement group_id="B3" value="911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression of Acute Coronary Syndrome to Myocardial Infarction</title>
        <description>Outcome for all participants during the first 24 hours of hospitalization; evidence of myocardial infarction is determined by ECG and biomarker results.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIK --</title>
            <description>GIK = glucose-insulin-potassium</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Progression of Acute Coronary Syndrome to Myocardial Infarction</title>
          <description>Outcome for all participants during the first 24 hours of hospitalization; evidence of myocardial infarction is determined by ECG and biomarker results.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Arrest</title>
        <description>Outcome for all participants who had a cardiac arrest from initial contact in the prehospital setting through their subsequent hospitalization.</description>
        <time_frame>1 to 18 hours (From prehospital setting through hospitalization.)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIK --</title>
            <description>GIK = glucose-insulin-potassium</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Arrest</title>
          <description>Outcome for all participants who had a cardiac arrest from initial contact in the prehospital setting through their subsequent hospitalization.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure or Death</title>
        <description>Outcome for all participants (composite of re-hospitalization for heart failure or death within 30 days)</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIK --</title>
            <description>GIK = glucose-insulin-potassium</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure or Death</title>
          <description>Outcome for all participants (composite of re-hospitalization for heart failure or death within 30 days)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Regression, Logistic</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Outcome for all participants (mortality at 30 days).</description>
        <time_frame>30 days</time_frame>
        <population>30 day mortality.</population>
        <group_list>
          <group group_id="O1">
            <title>GIK --</title>
            <description>GIK = glucose-insulin-potassium</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Outcome for all participants (mortality at 30 days).</description>
          <population>30 day mortality.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Regression, Logistic</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Arrest or Acute Mortality</title>
        <description>Outcome for all participants (composite of cardiac arrest or acute mortality)</description>
        <time_frame>Prehospital setting through hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIK --</title>
            <description>GIK = glucose-insulin-potassium</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Arrest or Acute Mortality</title>
          <description>Outcome for all participants (composite of cardiac arrest or acute mortality)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GIK --</title>
          <description>GIK = glucose-insulin-potassium</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Dextrose 5%</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkaelemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="411"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="147" subjects_affected="147" subjects_at_risk="411"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="411"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="411"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Co-Principal Investigator</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-8788</phone>
      <email>jbeshansky@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

